The gastro-intestinal system digests, absorbs, and then transports dietary nutrients. The small intestine is the major site of all three processes, where luminal contents-amino acids, sugars, fatty acids, cholesterol, and an assortment of minerals and micronutrients-are taken up by enterocytes, packaged and secreted into the circulation. Transport of neutral fats poses a unique problem in that the cargo is not water soluble. These dietary constituents are suspended in micelles within the lumen of the intestine through the surfactant action of bile; luminal lipases then liberate free fatty acids and cholesterol that can traverse the apical surface of the enterocytes (Fig. 1) . Following absorption, an evolutionarily conserved machinery resynthesizes neutral lipids for incorporation into chylomicrons, lipoprotein particles that are secreted across the basolateral surface of the enterocyte for delivery to the circulation where they are suspended for transport to sites of lipid delivery [1] .
Three autosomal recessive Mendelian causes of defective intestinal fat transport have been described (Fig. 1) . To varying degrees, each Mendelian disease of intestinal fat transport is marked by malnutrition, stunting of growth, fat-soluble vitamin deficiencies, and accumulation of fat in the intestine (intestinal lipidosis) and in the liver (hepatic steatosis). The first two diseases abetalipoproteinemia (OMIM: 200100) and hypobetalipoproteinemia (OMIM: 107730) cause defective assembly of nascent chylomicrons owing to mutations in the genes MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTTP), encoding the chylomicron packaging enzyme, and APOLIPOPROTEIN B (APOB), encoding the signature apolipoprotein of chylomicrons, respectively. The third single-gene disease in this category is chylomicron retention disease (CMRD; OMIM: 246700, also called Anderson disease), and the affected gene SAR1B encodes a guanosine triphosphatase that participates in the coat protein II (COPII)-coated vesicular transport of pre-chylomicrons from the endoplasmic reticulum to the Golgi apparatus [2] . In CMRD, initiation of chylomicron production is normal, but maturation and transport across the enterocyte's secretory system is impaired. From the initial positional cloning of the CMRD locus [3] and numerous subsequent reports, we have learned that nearly all the SAR1B lesions identified are point mutations or small insertion-deletions that inactivate the encoded protein's function. Like the rest of the machinery of chylomicron assembly, SAR1B is an ancient and highly conserved protein found in all eukaryotes [4] . Why loss of this protein's function causes a seemingly limited defect in enterocyte lipid transport is a fundamental question that has been stymied by lack of a robust animal model.
In this issue, Knapik and colleagues describe a zebrafish larval model of CMRD [5] . This organism has several technical advantages for studying lipid metabolism, with numerous validated tools for such investigation in both the larval and adult periods [6] . The authors first establish that sar1b messenger RNA (mRNA) is deposited maternally in oocytes. Over the course of the embryonic and larval period, robust sar1b expression becomes restricted to the intestine and head structures. The authors use translation initiation-disrupting antisense morpholino oligonucleotides (MOs) to knock down expression of the Sar1b protein. They confirm the MO reagent's activity, and show knockdown can be rescued through introduction of MOinsensitive mRNAs encoding both zebrafish Sar1b and human SAR1B proteins. The authors establish that sar1b MO-injected larvae develop intestinal lipidosis when fed a high-fat and highcholesterol meal, with numerous cytoplasmic lipid droplets accumulating in otherwise normal-appearing enterocytes.
The zebrafish sar1b knockdown model differs from human CMRD in one major respect: the rapidity of the growth defects. In addition to the intestinal transport defect, the authors note decreased endoderm-derived organ size and altered neural development in the MO-injected larvae within the short experimental window of the first week of life. This seeming acceleration of developmental arrest may reflect difference between the rapid embryonic growth of externally fertilized zebrafish embryos and the slower rate of growth experienced by placenta-fed human embryos. While the sar1b transcript does not appear to be strongly expressed in the yolk syncytial layer (YSL), the Sar1b protein is very likely to be present in this lipid-transporting cell type: an enhancer trap reporter construct inserted close to the 3′-end of the sar1b gene is expressed in the YSL [7] . Low-level protein expression of Sar1b in the YSL, very likely, explains the seemingly normal use of yolk lipids in sar1b MO-injected animals.
The severe growth retardation seen in sar1b MO-injected larvae is reminiscent of the severe phenotype of zebrafish larvae injected with mtp MOs (the zebrafish ortholog of human MTTP) [8] . The mtp MO-injected embryos also manifest defective absorption of maternally deposited yolk lipids; moreover, this defect appears more severe than the phenotype of a subsequently reported hypomorphic point mutation in mtp [8, 9] . The mtp mutant has a very interesting vascular patterning defect, reflecting altered lipoprotein-directed signaling to the endothelium [9] . These differences between strong MO-based knockdown phenotypes and chemical mutagen-induced hypomorphic alleles underscore the value of establishing more than one genetic model.
CMRD has a broad clinical spectrum, with neurological manifestations being the most variable [10] . Since the primary sequence of SAR1B proteins are highly conserved from plants to humans, I anticipate the authors will be able to make excellent use of new genome editing technologies to introduce human point mutations into the zebrafish sar1b locus to model the spectrum of CMRD phenotypes [11] . Conversely, they should be able to assess whether constitutive overactivity of Sarb1 causes any changes in chylomicron trafficking. Such knock-ins may allow the authors to perform juvenile and adult experiments, including more detailed physiological measurements of intestinal lipid transport, measurement of plasma lipids, and tracking the fate of radiotracer analogs of dietary lipids [12] . Such experiments might explain why a fluorescent cholesterol analog showed defective uptake by the intestines of the sar1b MO-injected larvae. Since this cholesterol analog is absorbed only in the presence of luminal fats [13] , the author's finding raises the possibility that intestinal Sar1b deficiency triggers alterations in gene expression that limit further cholesterol transport. The simplest molecular basis would be down-regulation of expression of the apical cholesterol transporter Npc1l1 (Fig. 1) . In cultured hepatocytes, Sar1b knockdown causes a coordinated down-regulation of cholesterol synthetic genes, suggesting a parallel method to limit accumulation of free cholesterol in the setting of defective very low-density lipoprotein secretion [14] .
Additionally, zebrafish Sar1b knock-in mutant models would allow comprehensive comparison of lipid trafficking gene expression between the intestine and liver. Indeed, the sar1b MO-injected larvae do not display hepatic steatosis, suggesting this phenotype takes longer to develop than the experimental window afforded by these transient knockdown reagents. Lastly, genetic zebrafish CMRD models would afford the opportunity to perform live imaging of lipid transport among organs, something that poses a major technical challenge in other organisms. Assessing how the very large prechylomicrons (250 nm in diameter) are "stuffed" into a COPII vesicle could be tackled with live imaging approaches, as could subsequent maturation of these particles to their final (>1-μm diameter) size. Loss-of-function studies on additional individual components of the COPII complex would address these questions directly [15, 16] . Collectively, modeling CMRD in zebrafish will yield insights into enterocyte lipid handling that could be of use not only to understand this rare and potentially devastating monogenetic illness but also to allow investigators to identify novel therapeutic targets for combatting pandemic obesity through modulating enterocyte transport of absorbed nutrients.
